NCT05483725View on ClinicalTrials.gov

Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.

Active, not recruitingOBSERVATIONAL

Enrollment

108

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

December 4, 2024

Study Completion Date

December 31, 2024

Conditions

Kidney DiseasesKidney Transplant; ComplicationsCOVID-19Vaccine Adverse ReactionRejection Acute RenalRejection Chronic Renal

Interventions

BIOLOGICAL

Booster dose of mRNA vaccine

Administration of SARS-CoV-2 mRNA vaccine.

Trial Locations (1)

14021

Institute for Clinical and Experimental Medicine, Prague

All Listed Sponsors

lead

Institute for Clinical and Experimental Medicine

OTHER_GOV

NCT05483725 - Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients. | Biotech Hunter | Biotech Hunter